Update on the Management of Acanthamoeba Keratitis

Colton McCoy, Shaivi Patel, Praneetha Thulasi

Research output: Contribution to journalArticlepeer-review


Purpose or Review: In this article, we review the latest diagnostic modalities and management of acanthamoeba keratitis Recent Findings: The incidence as well as severity of acanthamoeba keratitis is increasing, making this a challenging disease to treat, especially in patients who have a delay in diagnosis or severe disease at presentation. Newer tools such as voriconazole, miltefosine, and collagen crosslinking may be needed for infection control. Complications such as persistent infection, severe thinning, or perforation may necessitate surgical intervention. Summary: While traditional therapies such as polyhexamethylene biguanide and chlorhexidine remain mainstays of therapy, unresponsive acanthamoeba keratitis may benefit from topical or oral voriconazole, oral miltefosine, or collagen crosslinking. Despite these options, management of these patients remains a challenge.

Original languageEnglish
Pages (from-to)153-161
Number of pages9
JournalCurrent Ophthalmology Reports
Issue number4
StatePublished - Dec 2022


  • Acanthamoeba
  • Acanthamoeba keratitis
  • Collagen crosslinking
  • Infectious keratitis
  • Miltefosine


Dive into the research topics of 'Update on the Management of Acanthamoeba Keratitis'. Together they form a unique fingerprint.

Cite this